416 related articles for article (PubMed ID: 9124824)
21. Gyrase mutations in laboratory-selected, fluoroquinolone-resistant mutants of Mycobacterium tuberculosis H37Ra.
Kocagöz T; Hackbarth CJ; Unsal I; Rosenberg EY; Nikaido H; Chambers HF
Antimicrob Agents Chemother; 1996 Aug; 40(8):1768-74. PubMed ID: 8843279
[TBL] [Abstract][Full Text] [Related]
22. Mutant prevention concentrations for single-step fluoroquinolone-resistant mutants of wild-type, efflux-positive, or ParC or GyrA mutation-containing Streptococcus pneumoniae isolates.
Smith HJ; Walters M; Hisanaga T; Zhanel GG; Hoban DJ
Antimicrob Agents Chemother; 2004 Oct; 48(10):3954-8. PubMed ID: 15388458
[TBL] [Abstract][Full Text] [Related]
23. In vitro activities of novel nonfluorinated quinolones PGE 9262932 and PGE 9509924 against clinical isolates of Staphylococcus aureus and Streptococcus pneumoniae with defined mutations in DNA gyrase and topoisomerase IV.
Jones ME; Critchley IA; Karlowsky JA; Blosser-Middleton RS; Schmitz FJ; Thornsberry C; Sahm DF
Antimicrob Agents Chemother; 2002 Jun; 46(6):1651-7. PubMed ID: 12019071
[TBL] [Abstract][Full Text] [Related]
24. High-level fluoroquinolone resistance in Streptococcus pneumoniae requires mutations in parC and gyrA.
Janoir C; Zeller V; Kitzis MD; Moreau NJ; Gutmann L
Antimicrob Agents Chemother; 1996 Dec; 40(12):2760-4. PubMed ID: 9124836
[TBL] [Abstract][Full Text] [Related]
25. Contribution of mutations in gyrA and parC genes to fluoroquinolone resistance of mutants of Streptococcus pneumoniae obtained in vivo and in vitro.
Tankovic J; Perichon B; Duval J; Courvalin P
Antimicrob Agents Chemother; 1996 Nov; 40(11):2505-10. PubMed ID: 8913454
[TBL] [Abstract][Full Text] [Related]
26. Targeting of DNA gyrase in Streptococcus pneumoniae by sparfloxacin: selective targeting of gyrase or topoisomerase IV by quinolones.
Pan XS; Fisher LM
Antimicrob Agents Chemother; 1997 Feb; 41(2):471-4. PubMed ID: 9021211
[TBL] [Abstract][Full Text] [Related]
27. Sparfloxacin resistance in clinical isolates of Streptococcus pneumoniae: involvement of multiple mutations in gyrA and parC genes.
Taba H; Kusano N
Antimicrob Agents Chemother; 1998 Sep; 42(9):2193-6. PubMed ID: 9736534
[TBL] [Abstract][Full Text] [Related]
28. Comparison of gyrA and parC mutations and resistance levels among fluoroquinolone-resistant isolates and laboratory-derived mutants of oral streptococci.
Kaneko A; Sasaki J; Shimadzu M; Kanayama A; Saika T; Kobayashi I
J Antimicrob Chemother; 2000 Jun; 45(6):771-5. PubMed ID: 10837428
[TBL] [Abstract][Full Text] [Related]
29. Fluoroquinolone resistance in Streptococcus pneumoniae: evidence that gyrA mutations arise at a lower rate and that mutation in gyrA or parC predisposes to further mutation.
Gillespie SH; Voelker LL; Ambler JE; Traini C; Dickens A
Microb Drug Resist; 2003; 9(1):17-24. PubMed ID: 12705679
[TBL] [Abstract][Full Text] [Related]
30. Relationship between mutations in parC and gyrA of clinical isolates of Streptococcus pneumoniae and resistance to ciprofloxacin and grepafloxacin.
Stewart BA; Johnson AP; Woodford N
J Med Microbiol; 1999 Dec; 48(12):1103-1106. PubMed ID: 10591164
[TBL] [Abstract][Full Text] [Related]
31. Activities of fluoroquinolones against Streptococcus pneumoniae type II topoisomerases purified as recombinant proteins.
Morrissey I; George J
Antimicrob Agents Chemother; 1999 Nov; 43(11):2579-85. PubMed ID: 10543732
[TBL] [Abstract][Full Text] [Related]
32. Topoisomerase mutations in trovafloxacin-resistant Staphylococcus aureus.
Fitzgibbon JE; John JF; Delucia JL; Dubin DT
Antimicrob Agents Chemother; 1998 Aug; 42(8):2122-4. PubMed ID: 9687420
[TBL] [Abstract][Full Text] [Related]
33. Fluoroquinolone-resistant Streptococcus pneumoniae associated with levofloxacin therapy.
Urban C; Rahman N; Zhao X; Mariano N; Segal-Maurer S; Drlica K; Rahal JJ
J Infect Dis; 2001 Sep; 184(6):794-8. PubMed ID: 11517444
[TBL] [Abstract][Full Text] [Related]
34. Efflux and target mutations as quinolone resistance mechanisms in clinical isolates of Streptococcus pneumoniae.
Broskey J; Coleman K; Gwynn MN; McCloskey L; Traini C; Voelker L; Warren R
J Antimicrob Chemother; 2000 Apr; 45 Suppl 1():95-9. PubMed ID: 10824039
[TBL] [Abstract][Full Text] [Related]
35. Purification of pneumococcal type II topoisomerases and inhibition by gemifloxacin and other quinolones.
Morrissey I; George JT
J Antimicrob Chemother; 2000 Apr; 45 Suppl 1():101-6. PubMed ID: 10824040
[TBL] [Abstract][Full Text] [Related]
36. In-vitro and in-vivo activity of trovafloxacin against Streptococcus pneumoniae.
Klugman KP; Gootz TD
J Antimicrob Chemother; 1997 Jun; 39 Suppl B():51-5. PubMed ID: 9222070
[TBL] [Abstract][Full Text] [Related]
37. Fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae: contributions of type II topoisomerase mutations and efflux to levels of resistance.
Bast DJ; Low DE; Duncan CL; Kilburn L; Mandell LA; Davidson RJ; de Azavedo JC
Antimicrob Agents Chemother; 2000 Nov; 44(11):3049-54. PubMed ID: 11036021
[TBL] [Abstract][Full Text] [Related]
38. Ciprofloxacin dimers target gyrase in Streptococcus pneumoniae.
Gould KA; Pan XS; Kerns RJ; Fisher LM
Antimicrob Agents Chemother; 2004 Jun; 48(6):2108-15. PubMed ID: 15155208
[TBL] [Abstract][Full Text] [Related]
39. Comparison of in vitro antimicrobial activity of AM-1155 with those of tosufloxacin and fleroxacin against clinical isolates of Neisseria gonorrhoeae harboring quinolone resistance alterations in GyrA and ParC.
Deguchi T; Yasuda M; Nakano M; Ozeki S; Kanematsu E; Fukuda H; Maeda S; Saito I; Kawada Y
Chemotherapy; 1997; 43(4):239-44. PubMed ID: 9209780
[TBL] [Abstract][Full Text] [Related]
40. Fluoroquinolones: is there a different mechanism of action and resistance against Streptococcus pneumoniae?
Harding I; Simpson I
J Chemother; 2000 Oct; 12 Suppl 4():7-15. PubMed ID: 11131958
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
